Characterization of the main placental cytokine profiles from HIV-1-infected pregnant women treated with anti-retroviral drugs in France

Clinical and Experimental Immunology

Volumn 149, Issue 3, 2007, Pages 430-439

  Faye, A ^a,b   Pornprasert, S ^a,c   Mary, J Y ^b   Dolcini, G ^a,d   Derrien, M ^a   Barre Sinoussi F ^a   Chaouat, G ^b   Menu, E ^a  

^a INSTITUT PASTEUR   (France)

^b INSERM   (France)

^c CMU   (Thailand)

^d UNIVERSIDAD DE BUENOS AIRES   (Argentina)

Author keywords

Anti retroviral treatment; Cytokines; HIV 1; Mother to child transmission; Placenta

Indexed keywords

ANTIRETROVIRUS AGENT; CYTOKINE; INTERLEUKIN 10; INTERLEUKIN 16; INTERLEUKIN 8; LAMIVUDINE; LEUKEMIA INHIBITORY FACTOR; MESSENGER RNA; NELFINAVIR; NEVIRAPINE; RANTES; RNA DIRECTED DNA POLYMERASE INHIBITOR; STROMAL CELL DERIVED FACTOR 1; TUMOR NECROSIS FACTOR ALPHA; ZIDOVUDINE;

ADULT; ARTICLE; CESAREAN SECTION; CLINICAL ARTICLE; CONTROLLED STUDY; CORRELATION ANALYSIS; CYTOKINE RELEASE; ELECTIVE SURGERY; EXPLANT; FEMALE; FRANCE; GENE EXPRESSION; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1 INFECTION; HUMAN IMMUNODEFICIENCY VIRUS INFECTED PATIENT; HUMAN TISSUE; PLACENTA; PREGNANT WOMAN; PRIORITY JOURNAL; PROTEIN SECRETION; SUPERNATANT; T LYMPHOCYTE; TISSUE CULTURE; TREATMENT DURATION;

ADULT; ANTI-HIV AGENTS; CHEMOKINES, CXC; CYTOKINES; FEMALE; GENE EXPRESSION REGULATION; HIV INFECTIONS; HIV-1; HUMANS; INTERLEUKIN-8; LEUKEMIA INHIBITORY FACTOR; PLACENTA; PREGNANCY; PREGNANCY COMPLICATIONS, INFECTIOUS; RNA, MESSENGER; TISSUE CULTURE TECHNIQUES; TUMOR NECROSIS FACTOR-ALPHA; VIRAL LOAD;

EID: 34547873162     PISSN: 00099104     EISSN: 13652249     Source Type: Journal    
DOI: 10.1111/j.1365-2249.2007.03411.x     Document Type: Article

References (60)

1. Mandelbrot L, Landreau-Mascaro A, Rekacewicz C et al. Lamivudine-zidovudine combination for prevention of maternal-infant transmission of HIV-1. JAMA 2001 285 : 2083 93.
2. Cooper ER, Charurat M, Mofenson L et al. Combination anti-retroviral strategies for the treatment of pregnant HIV-1-infected women and prevention of perinatal HIV-1 transmission. J Acquir Immune Defic Syndr 2002 29 : 484 94.
3. Dorenbaum A, Cunningham CK, Gelber RD et al. Two-dose intrapartum/newborn nevirapine and standard anti-retroviral therapy to reduce perinatal HIV transmission: a randomized trial. JAMA 2002 288 : 189 98.
4. The European Collaborative Study. Mother-to-child transmission of HIV infection in the era of highly active anti-retroviral therapy. Clin Infect Dis 2005 40 : 458 65.
5. Magder LS, Mofenson L, Paul ME et al. Risk factors for in utero and intrapartum transmission of HIV. J Acquir Immune Defic Syndr 2005 38 : 87 95.
6. Brossard Y, Aubin JT, Mandelbrot L et al. Frequency of early in utero HIV-1 infection: a blind DNA polymerase chain reaction study on 100 fetal thymuses. AIDS 1995 9 : 359 66.
7. Rouzioux C, Costagliola D, Burgard M et al. Estimated timing of mother-to-child human immunodeficiency virus type 1 (HIV-1) transmission by use of a Markov model. The HIV Infection in Newborns French Collaborative Study Group. Am J Epidemiol 1995 142 : 1330 7.
8. Moussa M, Mognetti B, Dubanchet S et al. Vertical transmission of HIV: parameters which might affect infection of placental trophoblasts by HIV-1: a review. Biomed Group on the Study of In Utero Transmission of HIV 1. Am J Reprod Immunol 1999 41 : 312 9.
9. Derrien M, Faye A, Dolcini G, Chaouat G, Barre-Sinoussi F, Menu E. Impact of the placental cytokine-chemokine balance on regulation of cell-cell contact-induced human immunodeficiency virus type 1 translocation across a trophoblastic barrier in vitro. J Virol 2005 79 : 12304 10.
10. Burton GJ, Watson AL. The structure of the human placenta: implications for initiating and defending against virus infections. Rev Med Virol 1997 7 : 219 28.
11. Kilani RT, Chang LJ, Garcia-Lloret MI, Hemmings D, Winkler-Lowen B, Guilbert LJ. Placental trophoblasts resist infection by multiple human immunodeficiency virus (HIV) type 1 variants even with cytomegalovirus coinfection but support HIV replication after provirus transfection. J Virol 1997 71 : 6359 72.
12. Menu E, M'Bopi Keou FX, Lagaye S et al. Selection of maternal human immunodeficiency virus type 1 variants in human placenta. European Network for In Utero Transmission of HIV-1. J Infect Dis 1999 179 : 44 51.
13. Saito S. Cytokine network at the feto-maternal interface. J Reprod Immunol 2000 47 : 87 103.
14. Fox H. The development and structure of the placenta. In: Fox H, Pathology of the placenta, 2nd edn, pp. 1 42. London : WB Saunders Ltd, 1997.
15. Delage G, Moreau JF, Taupin JL et al. [In vitro modulation of the production of the cytokine HILDA/LIF, secreted by human endometrial explants: preliminary results]. Contracept Fertil Sex 1995 23 : 622 5.
16. Giess R, Tanasescu I, Steck T, Sendtner M. Leukaemia inhibitory factor gene mutations in infertile women. Mol Hum Reprod 1999 5 : 581 6.
17. Meisser A, Chardonnens D, Campana A, Bischof P. Effects of tumour necrosis factor-alpha, interleukin-1 alpha, macrophage colony stimulating factor and transforming growth factor beta on trophoblastic matrix metalloproteinases. Mol Hum Reprod 1999 5 : 252 60.
18. Bowen JM, Chamley L, Mitchell MD, Keelan JA. Cytokines of the placenta and extra-placental membranes: biosynthesis, secretion and roles in establishment of pregnancy in women. Placenta 2002 23 : 239 56.
19. Wegmann TG, Lin H, Guilbert L, Mosmann TR. Bidirectional cytokine interactions in the maternal-fetal relationship: is successful pregnancy a TH2 phenomenon? Immunol Today 1993 14 : 353 6.
20. Chaouat G, Assal Meliani A, Martal J et al. IL-10 prevents naturally occurring fetal loss in the CBA × DBA/2 mating combination, and local defect in IL-10 production in this abortion-prone combination is corrected by in vivo injection of IFN-tau. J Immunol 1995 154 : 4261 8.
21. Patterson BK, Behbahani H, Kabat WJ et al. Leukemia inhibitory factor inhibits HIV-1 replication and is upregulated in placentae from nontransmitting women. J Clin Invest 2001 107 : 287 94.
22. Tjernlund A, Fleener Z, Behbahani H et al. Suppression of leukemia inhibitor factor in lymphoid tissue in primary HIV infection: absence of HIV replication in gp130-positive cells. AIDS 2003 17 : 1303 10.
23. Cheret A, Le Grand R, Caufour P et al. RANTES, IFN-gamma, CCR1, and CCR5 mRNA expression in peripheral blood, lymph node, and bronchoalveolar lavage mononuclear cells during primary simian immunodeficiency virus infection of macaques. Virology 1999 255 : 285 93.
24. Maciaszek JW, Parada NA, Cruikshank WW, Center DM, Kornfeld H, Viglianti GA. IL-16 represses HIV-1 promoter activity. J Immunol 1997 158 : 5 8.
25. Berger EA, Murphy PM, Farber JM. Chemokines receptors as HIV-1 coreceptors: roles in viral entry, tropism and disease. Annu Rev Immunol 1999 17 : 657 700.
26. Clouse KA, Powell D, Washington I et al. Monokine regulation of human immunodeficiency virus-1 expression in a chronically infected human T cell clone. J Immunol 1989 142 : 431 8.
27. Folks TM, Clouse KA, Justement J et al. Tumor necrosis factor alpha induces expression of human immunodeficiency virus in a chronically infected T-cell clone. Proc Natl Acad Sci USA 1989 86 : 2365 8.
28. Shimoya K, Moriyama A, Matsuzaki N et al. Human placental cells show enhanced production of interleukin (IL) -8 in response to lipopolysaccharide (LPS), IL-1 and tumour necrosis factor (TNF)-alpha, but not to IL-6. Mol Hum Reprod 1999 5 : 885.
29. Weissman D, Poli G, Fauci AS. Interleukin 10 blocks HIV replication in macrophages by inhibiting the autocrine loop of tumor necrosis factor alpha and interleukin 6 induction of virus. AIDS Res Hum Retroviruses 1994 10 : 1199 206.
30. Weissman D, Poli G, Fauci AS. IL-10 synergizes with multiple cytokines in enhancing HIV production in cells of monocytic lineage. J Acquir Immune Defic Syndr Hum Retrovirol 1995 9 : 442 9.
31. Al-Harthi L, Guilbert LJ, Hoxie JA, Landay A. Trophoblasts are productively infected by CD4-independent isolate of HIV type 1. AIDS Res Hum Retroviruses 2002 18 : 13 7.
32. Menu E, Mognetti B, Moussa M et al. Insights into the mechanisms of vertical transmission of HIV-1. BIOMED2 Working Group on the in utero transmission of HIV-1. Early Pregnancy 1997 3 : 245 58.
33. Coulomb-L'Hermine A, Emilie D, Durand-Gasselin I, Galanaud P, Chaouat G. SDF-1 production by placental cells: a potential mechanism of inhibition of mother-to-fetus HIV transmission. AIDS Res Hum Retroviruses 2000 16 : 1097 8.
34. Behbahani H, Popek E, Garcia P et al. Up-regulation of CCR5 expression in the placenta is associated with human immunodeficiency virus-1 vertical transmission. Am J Pathol 2000 157 : 1811 8.
35. Lee BN, Ordonez N, Popek EJ et al. Inflammatory cytokine expression is correlated with the level of human immunodeficiency virus (HIV) transcripts in HIV-infected placental trophoblastic cells. J Virol 1997 71 : 3628 35.
36. Silvestri G, Feinberg MB. Turnover of lymphocytes and conceptual paradigms in HIV infection. J Clin Invest 2003 112 : 821 4.
37. Hazenberg MD, Otto SA, van Benthem BH et al. Persistent immune activation in HIV-1 infection is associated with progression to AIDS. AIDS 2003 17 : 1881 8.
38. Sousa AE, Carneiro J, Meier-Schellersheim M, Grossman Z, Victorino RM. CD4 T cell depletion is linked directly to immune activation in the pathogenesis of HIV-1 and HIV-2 but only indirectly to viral load. J Immunol 2002 169 : 3400 6.
39. Sperling RS, Shapiro DE, Coombs RW et al. Maternal viral load, zidovudine treatment, and the risk of transmission of human immunodeficiency virus type 1 from mother to infant. Pediatric AIDS Clinical Trials Group Protocol 076 Study Group. N Engl J Med 1996 335 : 1621 9.
40. Mofenson LM, Lambert JS, Stiehm ER et al. Risk factors for perinatal transmission of human immunodeficiency virus type 1 in women treated with zidovudine. Pediatric AIDS Clin Trials Group Study 185 Team. N Engl J Med 1999 341 : 385 93.
41. Taupin JL, Gualde N, Moreau JF. A monoclonal antibody based elisa for quantitation of human leukaemia inhibitory factor. Cytokine 1997 9 : 112 8.
42. Pornprasert S, Faye A, Mary JY et al. Down modulation of TNF-alpha mRNA placental expression by AZT used for the prevention of HIV-1 mother-to-child transmission. Placenta 2006 27 : 989 95.
43. Faye A, Pornprasert S, Dolcini G et al. Evaluation of the placental environment with a new in vitro model of histocultures of early and term placentae: determination of cytokines and chemokines expression profiles. Placenta 2005 26 : 262 7.
44. Sperling RS, Shapiro DE, McSherry GD et al. Safety of the maternal-infant zidovudine regimen utilized in the Pediatric AIDS Clinical Trial Group 076 Study. Aids 1998 12 : 1805 13.
45. Patterson BK, Tjernlund A, Andersson J. Endogenous inhibitors of HIV: potent anti-HIV activity of leukemia inhibitory factor. Curr Mol Med 2002 2 : 713 22.
46. Moussa M, Roques P, Fievet N et al. Placental cytokine and chemokine production in HIV-1-infected women: trophoblast cells show a different pattern compared to cells from HIV-negative women. Clin Exp Immunol 2001 125 : 455 64.
47. Zhou P, Goldstein S, Devadas K, Tewari D, Notkins AL. Human CD4+ cells transfected with IL-16 cDNA are resistant to HIV-1 infection: inhibition of mRNA expression. Nat Med 1997 3 : 659 64.
48. Feng Y, Broder CC, Kennedy PE, Berger EA. HIV-1 entry cofactor: functional cDNA cloning of a seven-transmembrane, G protein-coupled receptor. Science 1996 272 : 872 7.
49. Berger EA, Murphy PM, Farber JM. Chemokine receptors as HIV-1 coreceptors: roles in viral entry, tropism, and disease. Annu Rev Immunol 1999 17 : 657 700.
50. Zachar V, Fazio-Tirrozzo G, Fink T et al. Lack of protection against vertical transmission of HIV-1 by interferons produced during pregnancy in a cohort from East African republic of Malawi. J Med Virol 2000 61 : 195 200.
51. Lee BN, Hammill H, Popek EJ et al. Production of interferons and beta-chemokines by placental trophoblasts of HIV-1-infected women. Infect Dis Obstet Gynecol 2001 9 : 95 104.
52. Zachar V, Fink T, Koppelhus U, Ebbesen P. Role of placental cytokines in transcriptional modulation of HIV type 1 in the isolated villous trophoblast PG-839-47. AIDS Res Hum Retroviruses 2002 18 : 839 47.
53. Vidricaire G, Tardif MR, Tremblay MJ. The low viral production in trophoblastic cells is due to a high endocytic internalization of the human immunodeficiency virus type 1 and can be overcome by the pro-inflammatory cytokines tumor necrosis factor-alpha and interleukin-1. J Biol Chem 2003 278 : 15832 41.
54. Lallemant M, Jourdain G, Le Coeur S et al. Single-dose perinatal nevirapine plus standard zidovudine to prevent mother-to-child transmission of HIV-1 in Thailand. N Engl J Med 2004 35 : 217 28.
55. Guay LA, Musoke P, Fleming T et al. Intrapartum and neonatal single-dose nevirapine compared with zidovudine for prevention of mother-to-child transmission of HIV-1 in Kampala, Uganda: HIVNET 012 randomised trial. Lancet 1999 354 : 795 802.
56. Poirier MC, Olivero OA, Walker DM, Walker VE. Perinatal genotoxicity and carcinogenicity of anti-retroviral nucleoside analog drugs. Toxicol Appl Pharmacol 2004 199 : 151 61.
57. Poirier MC, Divi RL, Al-Harthi L et al. Long-term mitochondrial toxicity in HIV-uninfected infants born to HIV-infected mothers. J Acquir Immune Defic Syndr 2003 33 : 175 83.
58. Collier AC, Helliwell RJ, Keelan JA, Paxton JW, Mitchell MD, Tingle MD. 3′-azido-3′-deoxythymidine (AZT) induces apoptosis and alters metabolic enzyme activity in human placenta. Toxicol Appl Pharmacol 2003 192 : 164 73.
59. Blanche S, Tardieu M, Rustin P et al. Persistent mitochondrial dysfunction and perinatal exposure to anti-retroviral nucleoside analogues. Lancet 1999 354 : 1084 9.
60. Barret B, Tardieu M, Rustin P et al. Persistent mitochondrial dysfunction in HIV-1-exposed but uninfected infants: clinical screening in a large prospective cohort. Aids 2003 17 : 1769 85.